article · Metabolites
Teas derived from Camellia sinensis, including white, green, and oolong varieties, are known to have anti-obesity and lipid-lowering characteristics. In laboratory assays, a mixture of these teas demonstrated stronger inhibition of pancreatic lipase and alpha-amylase than the individual teas and standard reference drugs. Following this, the tea mixture was prepared into a nanoparticle formulation and tested in rats to assess its physiological impact. The treatment significantly lowered serum glucose and triglyceride levels. At the genetic level, it increased the expression of markers associated with lipolysis, such as GLUT-4, P-AMPK, Sirt-1, and PPAR-gamma, while suppressing genes linked to inflammation and adipogenesis, including TNF-alpha and ADD1/SREBP-1c. These results demonstrate that the nano-formulation counteracts obesity-related mechanisms via the AMPK/Sirt-1/GLUT-4 biological pathway.
Obesity and related metabolic disorders present major public health challenges globally. By demonstrating that a nano-formulation of common tea extracts can regulate key metabolic and inflammatory pathways in animal models, this research highlights potential natural therapeutic strategies for managing body weight and glucose levels.
This research could support the development of plant-derived therapeutic agents or nutraceutical formulations targeting obesity and related metabolic conditions. Potential users include pharmaceutical developers and functional food manufacturers. Because the findings are currently based on in vitro assays and an in vivo rat model, the technology remains at an early, pre-clinical stage of development and requires clinical validation before commercial use.
AI-generated from the published abstract. Always read the original work before citing.
White, green, and oolong teas are produced from the tea plant (Camellia sinensis (L.) Kuntze) and are reported to have anti-obesity and hypolipidemic effects. The current study aims to investigate the anti-obesity effects of a tea mixture nano-formulation by targeting the AMPK/Sirt-1/GLUT-4 axis in rats. In vitro lipase and α-amylase inhibition assays were used to determine the active sample, which was then incorporated into a nanoparticle formulation subjected to in vivo anti-obesity testing in rats by measuring the expression level of different genes implicated in adipogenesis and inflammation using qRT-PCR. Moreover, metabolomic analysis was performed for each tea extract using LC/ESI MS/MS coupled to chemometrics in an attempt to find a correlation between the constituents of the extracts and their biological activity. The in vitro pancreatic lipase and α-amylase inhibition assays demonstrated more effective activity in the tea mixture than the standards, orlistat and acarbose, respectively, and each tea alone. Thus, the herbal tea mixture and its nanoparticle formulation were evaluated for their in vivo anti-obesity activity. Intriguingly, the tea mixture significantly decreased the serum levels of glucose and triglycerides and increased the mRNA expression of GLUT-4, P-AMPK, Sirt-1, and PPAR-γ, which induce lipolysis while also decreasing the mRNA expression of TNF-α and ADD1/SREBP-1c, thereby inhibiting the inflammation associated with obesity. Our study suggests that the tea mixture nano-formulation is a promising therapeutic agent in the treatment of obesity and may also be beneficial in other metabolic disorders by targeting the AMPK/Sirt-1/Glut-4 pathway.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/metabo13070871
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
